Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;7(Suppl 4):S329-S333.
doi: 10.21037/tlcr.2018.12.02.

Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Chiara Lazzari  1 , Vanesa Gregorc  1 , Alessandra Bulotta  1 , Alessia Dottore  2 , Giuseppe Altavilla  2 , Mariacarmela Santarpia  2
Affiliations
Editorial

Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Chiara Lazzari et al. Transl Lung Cancer Res. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
PARPs are involved in the repair of single-strand DNA breaks (SSBs). They bind to the site of DNA damage, and induce poly(ADP-ribosyl)ation (PARylation), that is required to activate those enzymes implicated in DNA repair. PARP-inhibitors compete with NAD+, thus preventing the PARylation process. PARP-inhibitors are particularly effective in SLFN11 positive tumors. (A) The hypothesis that SLFN11 removes replication protein A (RPA), a protein that prevents SSBs; (B) the hypothesis that SLFN11 induces prolonged S-phase arrest, thus favoring the accumulation of DNA replication, and enhancing apoptosis, especially in the presence of PARP-inhibition. Yellow stars represent RPA. PARP, poly (ADP-ribose) polymerase.
See this image and copyright information in PMC

Comment on

References

    1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44. 10.1200/JCO.2005.04.4859 - DOI - PubMed
    1. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7. 10.1200/JCO.2006.06.5821 - DOI - PubMed
    1. Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017;14:549-61. 10.1038/nrclinonc.2017.71 - DOI - PMC - PubMed
    1. Santarpia M, Daffina MG, Karachaliou N, et al. Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res 2016;5:51-70. - PMC - PubMed
    1. Sen T, Gay CM, Byers LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Transl Lung Cancer Res 2018;7:50-68. 10.21037/tlcr.2018.02.03 - DOI - PMC - PubMed